In Brief
This article was originally published in The Tan Sheet
Executive Summary
Novartis narrows consumer decline in Q4; Abbott sanguine on China market; FDA warns Food for Health International; Suspect studies taint Bio-Strath claims, NAD says; NACDS debuts Total Store Expo; more news In Brief.
You may also be interested in...
In Brief
Novartis OTC plant not “out of the woods”; ERSP questions Calmestra claims; GSK seeks to switch Pirinase Hayfever Relief to GSL in U.K.; Kaneka raises CoQ10 prices; FTC to disburse consumer refund for Iovate supplements; more In brief.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.